Probuphine Panel Review Could Be A Test Of Titan’s Delivery Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will convene an advisory committee review of the buprenorphine implant for opioid dependence – an established use for the drug, but the first in an extended-release delivery system.